Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.
Saved in:
| Title: | Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis. |
|---|---|
| Authors: | Saxena A; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.; Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States., Yorker M; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Zorko NA; Department of Medicine, Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN 55455, United States., Narayan V; Department of Medical Oncology, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States., Siddiqui BA; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Saraiya B; Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States., Tester WJ; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Mille PJ; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Shaver AL; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Nikita N; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Lu-Yao GL; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Kelly WK; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States., Zarrabi KK; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States. |
| Source: | The oncologist [Oncologist] 2026 May 08; Vol. 31 (6). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42081291 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Saxena+A%22">Saxena A</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.; Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.<br /><searchLink fieldCode="AU" term="%22Yorker+M%22">Yorker M</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Zorko+NA%22">Zorko NA</searchLink>; Department of Medicine, Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN 55455, United States.<br /><searchLink fieldCode="AU" term="%22Narayan+V%22">Narayan V</searchLink>; Department of Medical Oncology, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.<br /><searchLink fieldCode="AU" term="%22Siddiqui+BA%22">Siddiqui BA</searchLink>; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Saraiya+B%22">Saraiya B</searchLink>; Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States.<br /><searchLink fieldCode="AU" term="%22Tester+WJ%22">Tester WJ</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Mille+PJ%22">Mille PJ</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Shaver+AL%22">Shaver AL</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Nikita+N%22">Nikita N</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Lu-Yao+GL%22">Lu-Yao GL</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Kelly+WK%22">Kelly WK</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.<br /><searchLink fieldCode="AU" term="%22Zarrabi+KK%22">Zarrabi KK</searchLink>; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 May 08; Vol. 31 (6). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42081291 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/oncolo/oyag172 Languages: – Code: eng Text: English Titles: – TitleFull: Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Saxena A – PersonEntity: Name: NameFull: Yorker M – PersonEntity: Name: NameFull: Zorko NA – PersonEntity: Name: NameFull: Narayan V – PersonEntity: Name: NameFull: Siddiqui BA – PersonEntity: Name: NameFull: Saraiya B – PersonEntity: Name: NameFull: Tester WJ – PersonEntity: Name: NameFull: Mille PJ – PersonEntity: Name: NameFull: Shaver AL – PersonEntity: Name: NameFull: Nikita N – PersonEntity: Name: NameFull: Lu-Yao GL – PersonEntity: Name: NameFull: Kelly WK – PersonEntity: Name: NameFull: Zarrabi KK IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 05 Text: 2026 May 08 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 31 – Type: issue Value: 6 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |
